Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ZYTIGA is substantial. |
Clinical Added Value
| moderate |
ZYTIGA provides a moderate improvement in actual benefit (level III) in terms of efficacy and tolerance in the treatment of metastatic castration-resistant prostate cancer which progresses during or after docetaxel therapy. |
eNq1mF1v2jAUhu/5FVEudkdC+FjLllBtrN2QWpVR0KbdIJMcwCzYqT/46K+fQ+gKk6OuBl8mdt5z7HP8+FXCq80ydVbAOKYkcgOv5jpAYppgMovc0fCmeuledSrhAq3Qy7S6mucFgevEKeI8cvNRbwKIcO/n3e0XUN8DczsVJ6STBcTiaJ4UOPW+IT6/Q1k+xwlXFCfOEsScJpGbSbF764RcMJVFZ03Zb56hGEJ//+ZwdDFuHr4P/VzsP1QlB3aLyEwrCsRIM5aMARFdJGBG2bYk34aRNuYD4FSyGPpIzPuMrnACiTbEFKUcjIJM18kDsFUKIg+iFfcX8ZIbiaMF2gzgsadP+pMa7YqNqNaqwUW7FjQvmvXWRa1uFIodbJW+CmoRfjwO6o2g1a75QPynrcAzZFiaPmUCpZaKgnn3uK8sxWHw+GrxE8yzFG29Bc9MtwoxpIaBqdNvbyH5CoZM8ShVe/aPPpFp6r8x69GeFpYyzmHUpZKIEmjcDEw3okuJgE15Rc04Jzb7XsTAzyf7RIme8X05SXFsSjTFHAlcjAa9cqCdkQWfEYcRsweDH5gkdM3PD5nDolrKPttxUiuasSQY19uX74NWy/gM/VIdVHK/XEtGM/AVfjA/hSo9MqWn8kQ1pV7quSXP1Y07k0NjlEKJzakakkW14bMrs9bo9g5RMaAV/Xo9NO2O7xLY9mH3qJXGSfS3rmbYtcFy1YuvJV6c2igbN2qty3aj+Q4ts4/P/jky9MqFqBWrLJkeMXMhMv7B99frtTdHvMqR2k9vykpvgCvtys+xeoXbl2LaM/NWbv/CDRWotZT6pLhD31ZF03P7mj841fPuv997a20MwSScUIsC8dZA3Ls+P9tfDK+1tPtHhLEXZmdOkcCU2HJNcqJVPO02UXUlN0wB4n46xSU/V0r7MvSLHzudSujnP3U6lT+7C/7A
CGZARyJXpV2LcmLP
